← Back to Clinical Trials
Recruiting NCT07781306

NCT07781306 PrOspEctive Metastases Imaging (POEM)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07781306
Status Recruiting
Phase
Sponsor Cancer Research Antwerp
Condition Liver Metastases
Study Type OBSERVATIONAL
Enrollment 50 participants
Start Date 2020-09-08
Primary Completion 2027-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 50 participants in total. It began in 2020-09-08 with a primary completion date of 2027-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a non-interventional, observational study with an optional interventional biobanking activity. Liver metastases of patients undergoing partial hepatectomy will be sampled completely while respecting the orientation used for medical imaging, in order to correlate the histopathological growth patterns in a 3D-map with the imaging characteristics. The full pathological sampling will only use remnant tissue.

Eligibility Criteria

Inclusion Criteria: 1. ≥ 18 years old. 2. Patients with liver metastatic colorectal or breast carcinoma undergoing a surgical excision of the liver metastases 3. Therapy-naive patients as well as patients with neo-adjuvant therapy are eligible for inclusion 4. Willingness of the patient to participate in this study demonstrated by signed written informed consent Exclusion Criteria: 1. Patients without MRI or CT of the liver prior to surgery 2. Time interval between medical imaging, CT and/or MRI is more than 12 weeks (nb: time interval is preferably less than 4 weeks but this is not an exclusion criterium) 3. Prior radiofrequency ablation (RFA) or transarterial chemoembolization (TACE) on the liver metastasis that would be operated

Contact & Investigator

Central Contact

Peter Vermeulen, MD, PhD

✉ peter.vermeulen@zas.be

📞 0032493194745

Frequently Asked Questions

Who can join the NCT07781306 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Liver Metastases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07781306 currently recruiting?

Yes, NCT07781306 is actively recruiting participants. Contact the research team at peter.vermeulen@zas.be for enrollment information.

Where is the NCT07781306 trial being conducted?

This trial is being conducted at Wilrijk, Belgium.

Who is sponsoring the NCT07781306 clinical trial?

NCT07781306 is sponsored by Cancer Research Antwerp. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology